Background and Aims: An acute hypercapnic respiratory failure (AHRF) due to acute exacerbation chronic obstructive pulmonary disease (AECOPD) causing a life-threatening. Initial treatment by optimizing medical management and supplemental oxygen were better than mechanical ventilation.
ray. Management AHRF was conducted including a supplemental oxygen -non rebreathing mask (NRM) 10 L/m, repeated combination of shortacting inhaled β 2 agonists (SABA) and short-acting muscarinic antagonist (SAMA), inhaled long-acting muscarinic antagonists (LAMA), two puffs respimat inhaler of tiotropium bromide, i.v methylprednisolone, aminophylline infusion, quinolone, i.v furosemid and amlodipine besylate.
Results: The symptoms were reduced after 2 h observation and was being stabil condition, RR 0f 24/min, BP was 140/90 mmHg, AGD results were improving by pH of 7.47, pO 2 = 86 mmHg, pCO 2 = 32.7 mmHg, HCO 3 = 23.6 meq/L after 24 h observation.
Conclusion:
An optimizing medical management of AHRF can prevent a life-threatening and death. We reported the using of tiotropium bromide or LAMA for hypercapnic respiratory failure. A very slow dissociation of tiotropium bromide from muscarinic receptors (M 1 and M 3 ) cause long broncodilation and a faster dissociation from M 2 -receptors cause vasoconstriction immediately to overcome vasodilatation caused by hypercapnia or CO 2 retention. The clinical studies are needed to investigate the use of inhaled LAMA especially tiotropium bromide during hypercapnic respiratory failure. Background and Aims: The ICU mortality in severe sepsis patient is still high. In this study, we wish to know that which clinical parameter and serum biomarker over time will influence ICU mortality in sepsis patients mostly.
Methods: A combined retrospective and prospective observational study from a cohort of adult sepsis patients admitted to three medical ICUs at Kaohsiung Chang Gung Memorial Hospital in Taiwan between August 2013 and June 2016. At each sepsis patients admitted to medical ICU, clinical parameters such as Apache II score, SOFA score, PaO 2 / FiO 2 values, and serum biomarkers such as CRP, albumin, lactate, procalcitonin were studied on day 1, day 3, day 7 after ICU admission for severity evaluation.
Results: A total 782 severe sepsis patients admitted to medical ICU in this period. We found that 210 patients were ICU non-survivors and 572 patients were ICU survivors. In this study, we can see the level of serum biomarkers such as CRP3, CRP7, PCT7, lactate 1, lactate 3, lactate 7 were higher and albumin 1, albumin 3 were lower for ICU mortality in severe sepsis. Clinical parameter scoring such as Apache II score, SOFA 1, SOFA 3, SOFA 7 were higher for ICU mortality and the values of PaO 2 /FiO2 1, PaO 2 /FiO 2 3, PaO 2 /FiO 2 7 were lower for ICU mortality in severe sepsis patients. By multivariate analysis, we can see CRP 7, SOFA 7, PaO 2 /FiO 2 1 values were the independent factors for predicting ICU mortality.
Severe sepsis is a complex disease and little clinical parameters and serum biomarkers would predict ICU mortality. In this retrospective cohort, we set much clinical parameters and serum biomarkers over time and use multivariate analysis method to search possible factors for ICU mortality. Finally, we find that CRP 7, SOFA 7, PaO 2 /FiO 2 1 values were the independent factors for predicting ICU mortality in severe sepsis patients. Background and Aims: Literature regarding 90-day mortality in MICU patients is limited. Lactate and procalcitonin are used worldwide as markers for sepsis and shock, however their use as a predictor of mortality in sepsis has not been assessed. This study aims to examine the clinical profile and determinants of 90-day mortality in MICU admissions, and ability of lactate*procalcitonin product on admission to predict mortality in a subgroup with sepsis.
Methods: Data from 538 consecutive MICU admissions to Tan Tock Seng Hospital, Singapore, in 2015 was analyzed using multivariable logistic regression to evaluate independent predictors of 90-day mortality. The ability of lactate, procalcitonin and lactate*procalcitonin to predict mortality was assessed using area under the receiver operating characteristic curve (AUROC).
Results: The 90-day mortality was 45.5%. Mean age was 65 (SD 15) years. Sequential organ failure assessment (SOFA) score, lactate on admission, and Pulseless Electrical Activity (PEA) on arrival were independent predictors of mortality (Table 1) . In sepsis subgroup, lactate was a significant predictor of mortality (P = 0.006) AUROC 0.63, while the lactate*procalcitonin product did not show significant association with mortality. A history of Chronic Obstructive Pulmonary Disease (COPD) was not associated with an increased mortality. 
